The purpose of this article is to focus on anti-allergic therapies that directly target cellular or humoral actors of the allergic reaction and which are quasi-exclusively dedicated to the treatment of allergic diseases. This leads to successively look at: anti-histamines, classic treatments but in constant improvement, allergen immunotherapy which is experiencing a second life with the validation of the sublingual route and monoclonal anti-IgE antibody, a real new therapeutic class which has demonstrated his efficacy in patients with severe non-controlled allergic asthma.